About PostEra
PostEra is building a modern 21st century biopharma that uses artificial intelligence to transform drug discovery. The company has developed Proton, an end-to-end machine learning platform that closes the Design-Make-Test cycle of medicinal chemistry. PostEra focuses on the chemistry stage of drug discovery, addressing the iterative three-step cycle of designing molecules, synthesizing them, and testing their properties. Their platform combines proprietary data with chemistry foundation models to design molecules that satisfy the competing properties required for drug candidates, while state-of-the-art synthesis planning ensures every designed molecule has a reliable synthetic route. PostEra advances small molecule programs through partnerships with leading biopharma companies while also developing its own internal pipeline. The company has established over $1 billion in AI partnerships with major pharmaceutical companies including Pfizer and Amgen, as well as the NIH. PostEra also launched and led COVID Moonshot, the world's largest open-science drug discovery effort. The company's mission is to accelerate medicinal chemistry and bring more cures to patients by making drug discovery faster, more optimized, and more successful.
Mission & Story
Mission
PostEra is building a modern 21st century biopharma. We use Proton, our AI platform for medicinal chemistry, to accelerate the discovery of new medicines for patients.
Who It Serves
Milestones & Awards
Recent Milestones
January 2025: Expanded Pfizer collaboration to $610M. October 2023: Added Amgen collaboration bringing total AI partnerships to $1Bn. March 2024: Progress update on Pfizer AI Lab with third target nominated. December 2021: Established $260M AI Lab with Pfizer and closed $24M Series A.
Key Partnerships
Company Details
- Employees
- 51-200
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.